Online inquiry

IVTScrip™ mRNA-Anti-NRP1, MNRP1685A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12036MR)

This product GTTS-WQ12036MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets NRP1 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001024628.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 8829
UniProt ID O14786
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-NRP1, MNRP1685A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ12036MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8485MR IVTScrip™ mRNA-Anti-ITGAL, hu1124(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA hu1124
GTTS-WQ1392MR IVTScrip™ mRNA-Anti-IL1A&IL1B, ABT-981(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ABT-981
GTTS-WQ4387MR IVTScrip™ mRNA-Anti-B7, BMS-224818(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BMS-224818
GTTS-WQ15146MR IVTScrip™ mRNA-Anti-FCGRT, SYNT-001(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA SYNT-001
GTTS-WQ4777MR IVTScrip™ mRNA-Anti-TNFSF13B, BR3-Fc(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BR3-Fc
GTTS-WQ14026MR IVTScrip™ mRNA-Anti-IL33, REGN-3500(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA REGN-3500
GTTS-WQ6829MR IVTScrip™ mRNA-Anti-IL3RA, DT-IL-3(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA DT-IL-3
GTTS-WQ12794MR IVTScrip™ mRNA-Anti-NOTCH2&NOTCH3, OMP-59R5(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA OMP-59R5
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW